此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset (PROST-3)

2026年11月11日 更新者:Tasly Biopharmaceuticals Co., Ltd.

A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

研究概览

详细说明

Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and <=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 <= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.

研究类型

介入性

注册 (估计的)

978

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国
        • Beijing Tiantan Hospital, Capital Medical University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age >=18 years, male or female;
  2. Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
  3. Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
  4. Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
  5. NIHSS score of 6 to 25 (inclusive);
  6. Pre-stroke mRS score <2;
  7. No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
  8. The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form.

Exclusion Criteria:

  1. Unable to complete CTP/CTA or PWI/DWI/MRA examination;
  2. Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
  3. Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
  4. Previous history of intracranial hemorrhage;
  5. Major head trauma or ischemic stroke within the past 3 months;
  6. Intracranial tumor or giant intracranial aneurysm;
  7. Intracranial or intraspinal surgery within the past 3 months;
  8. Gastrointestinal or urinary tract bleeding within the past 3 weeks;
  9. Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
  10. Arterial puncture at a non-compressible site within the past 1 week;
  11. Active internal bleeding;
  12. Aortic arch dissection;
  13. Bacterial endocarditis or pericarditis;
  14. Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
  15. Acute bleeding tendency, including platelet count <100 x 10^9/L;
  16. Treatment with low-molecular-weight heparin or heparin within 24 hours;
  17. Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
  18. Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7;
  19. Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
  20. Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
  21. Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
  22. Severe renal insufficiency (eGFR <30 mL/min/1.73 m^2);
  23. Any terminal illness with a life expectancy of less than 1 year;
  24. Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products;
  25. Pregnant or lactating women;
  26. Participation in another clinical trial within the past 1 month;
  27. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:rhPro-UK Group

Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be >4.5 hours and <=24 hours after stroke onset.

Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion).

有源比较器:Standard of Care (SOC) Group

Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration.

Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)
大体时间:90 days after treatment

Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment.

90 days after treatment

次要结果测量

结果测量
措施说明
大体时间
Distribution of mRS Scores
大体时间:90 days after treatment

Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment

90 days after treatment
Proportion of Participants Achieving Functional Independence (mRS 0-2)
大体时间:90 days after treatment

Proportion of participants with an mRS score of 0-2 at 90 days after treatment.

90 days after treatment
Proportion of Participants With Early Neurological Improvement at 24 Hours
大体时间:24 hours after treatment

Proportion of participants with a decrease of >=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score <=1, at 24 hours after treatment.

24 hours after treatment
Proportion of Participants With Neurological Improvement at Day 7
大体时间:7 days after treatment

Proportion of participants with a decrease of >=4 points in NIHSS score from baseline, or an NIHSS score <=1, at 7 days after treatment.

7 days after treatment
Change From Baseline in NIHSS Score at 24 Hours
大体时间:Baseline and 24 hours after treatment

Change in NIHSS score from baseline at 24 hours after treatment.

Baseline and 24 hours after treatment
Change From Baseline in NIHSS Score at Day 7
大体时间:Baseline and 7 days after treatment

Change in NIHSS score from baseline at 7 days after treatment.

Baseline and 7 days after treatment
Proportion of Participants With a Barthel Index of 95-100
大体时间:90 days after treatment

Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment.

90 days after treatment
Proportion of Participants Achieving Reperfusion at 24 Hours
大体时间:24 hours after treatment

Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a >90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) >6 seconds.

24 hours after treatment
Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy
大体时间:Before mechanical thrombectomy (Day 0)

Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy).

Before mechanical thrombectomy (Day 0)
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition
大体时间:Within 36 hours after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria.

Within 36 hours after treatment
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition
大体时间:Within 7 days after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 7 Days
大体时间:Within 7 days after treatment

Incidence of death from any cause within 7 days after treatment.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 90 Days
大体时间:Within 90 days after treatment
Within 90 days after treatment
Incidence of Major Bleeding Events Within 7 Days
大体时间:Within 7 days after treatment
Within 7 days after treatment
Incidence of Intracranial Hemorrhage Events Within 7 Days
大体时间:Within 7 days after treatment

Within 7 days after treatment

Within 7 days after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月30日

初级完成 (估计的)

2029年3月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • TSL-BIO2601-AIS24-Ⅲ
  • NMPA IND No. (其他标识符:2026LP02152)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅